Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scotland adopts NICE (UK National Institute for Clinical Excellence) guidance on PDT (photodynamic therapy):

This article was originally published in Clinica

Executive Summary

NHS Quality Improvement Scotland has advised that guidance issued by the National Institute for Clinical Excellence (NICE) on the provision of photodynamic therapy for age-related macular degeneration is as valid for Scotland as for England and Wales. A Verteporfin Photodynamic Therapy Cohort Study developed by the Royal College of Ophthalmologists will be used, says the NHSQIS, to collect outcomes of the treatment of predominantly classic choroidal neovascularisation (CNV) and other clinical and cost-effectiveness data needed to inform future use of the technology. NHSScotland is considering how best to identify patients for treatment. NICE recommended researching the potential for population screening of the condition (see Clinica No 1076, p 6).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT063838

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel